RSPI RespireRx Pharmaceuticals Dashboard

Cannabinoids is a broad term to describe the pharmacologically active naturally occurring substances found within the cannabis (marijuana) plant. While the liberalization of state laws regulating the use and sales of marijuana has created a major industry based on the commercialization of marijuana for both medical and recreational use, the U.S. Food and Drug Administration (“FDA”) has not recognized or approved the marijuana plant as medicine nor is it federally legal to sell products that contain cannabinoids as drugs, dietary supplements or foods (edibles) without its approval. From a scientific and pharmaceutical perspective, however, we do not think that pharmaceutical cannabinoids should suffer from the stigma that marijuana has, since it was declared a controlled substance in the 1930’s. We believe that cannabinoids should be considered pharmaceuticals developed under FDA and comparable international regulatory bodies that happen to have been originally derived from plants much like aspirin, theophylline or tamoxifen.

Company profile

Ticker

RSPI, RSPID

Exchange

OTC

Website

www.respirerx.com

CEO

Arnold S. Lippa

Incorporated

Delaware

Location

New Jersey

Fiscal year end

Dec 31

Sector

Health Technology > Pharmaceuticals

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Merck & Co • Allergan • Johnson & Johnson • Abbott Laboratories • Teva- Pharmaceutical Industries • Viatris • Bristol-Myers Squibb • Lilly(Eli) & Co • Warner Chilcott ...

Former names

CORTEX PHARMACEUTICALS INC/DE/

SEC CIK

0000849636

Corporate docs

Articles of Incorporation & Bylaws

IRS number

330303583

RSPI stock data

S&P 500

1M 1Y 2Y 5Y

Press releases

Pro users get this 30m faster

Corrected Headline: RespireRx Pharmaceuticals Up Listed to OTCQB and Ticker Returns to RSPI

8 Feb 21

Glen Rock, N.J., Feb. 08, 2021 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB:RSPI) ("RespireRx" or the "Company" or "we"), has been up listed from the OTC Pink Market and returns to the OTCQB Venture

RespireRx Pharmaceuticals Inc. Announces 10 to 1 Reverse Stock Split

8 Feb 21

Investment data

Data from SEC filings

Securities sold

Number of investors

Calendar

31 Mar 21

13 Apr 21

31 Dec 21

Financial summary

Financial statements Chart RSPI financial data

Quarter (USD)	Sep 20	Jun 20	Mar 20	Sep 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 19	Dec 18	Dec 17	Dec 16
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated)	Burn method: Change in cash		Burn method: Operating income/loss		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	216	216	216	216	216	216
Cash burn (monthly)	425.33	(positive/no burn)	437.33K	239.99K	81.43K	33.18K
Cash used (since last report)	2.76K	n/a	2.84M	1.56M	528.15K	215.2K
Cash remaining	-2.54K	n/a	-2.84M	-1.56M	-527.94K	-214.99K
Runway (months of cash)	-6.0	n/a	-6.5	-6.5	-6.5	-6.5

Beta Read what these cash burn values mean

Recent insider trades

RSPI insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
30 Sep 20	Jeff Eliot Margolis	Common Stock	Conversion	Aquire C	Yes	No	0	5,017,144	0	5,142,351
30 Sep 20	Jeff Eliot Margolis	Common Stock	Conversion	Aquire C	Yes	No	0	5,017,144	0	5,142,351
30 Sep 20	Jeff Eliot Margolis	Common Stock	Conversion	Aquire C	Yes	No	0	91,871,094	0	96,151,863
30 Sep 20	Jeff Eliot Margolis	Warrants (to purchase Common Stock) Common Stock	Conversion	Aquire C	Yes	No	0.007	5,017,144	35.12K	5,017,144
30 Sep 20	Jeff Eliot Margolis	Warrants (to purchase Common Stock) Common Stock	Conversion	Aquire C	Yes	No	0.007	5,017,144	35.12K	5,017,144
30 Sep 20	Jeff Eliot Margolis	Warrants (to purchase Common Stock) Common Stock	Conversion	Aquire C	Yes	No	0.007	91,871,094	643.1K	91,871,094
30 Sep 20	Jeff Eliot Margolis	Series H Preferred Stock Conversion Units	Gift	Aquire G	Yes	No	0.0064	7	0.04	32.11
30 Sep 20	Jeff Eliot Margolis	Series H Preferred Stock Conversion Units	Gift	Dispose G	No	No	0.0064	7	0.04	0
30 Sep 20	Jeff Eliot Margolis	Series H Preferred Stock Conversion Units	Gift	Aquire G	Yes	No	0.0064	7	0.04	32.11
30 Sep 20	Jeff Eliot Margolis	Series H Preferred Stock Conversion Units	Gift	Dispose G	No	No	0.0064	7	0.04	7

Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q1 2021

RSPI institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

13F holders	Current	Prev Q	Change
Total holders	0	0
Opened positions	0	0
Closed positions	0	0
Increased positions	0	0
Reduced positions	0	0

13F shares	Current	Prev Q	Change
Total value	0	0
Total shares	0	0
Total puts	0	0
Total calls	0	0
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change

Largest transactions	Shares	Bought/sold	Change

Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

Management Discussion

The Company’s unaudited consolidated statements of operations as discussed herein are presented below.

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: absorb, ADME, Alexa, amnesia, ascending, Attorney, auxiliary, began, behalf, bench, beneficiary, biotechnology, bona, book, broaden, broadly, brought, buy, calendar, candidate, caution, cautionary, certainty, chain, choose, civil, CMC, coined, commensurate, compete, confidence, consumer, consuming, contemplated, correct, correspondingly, cure, customer, Dawn, deadline, deal, decline, delisted, deposit, deposited, designee, desist, Dickason, difficulty, diminished, director, discourage, dispose, disposing, disproportionately, divert, dividend, downgrade, downturn, duty, economy, Emily, encounter, endocannabinoid, environment, exacerbated, excretion, exert, exerting, expend, expended, expenditure, fail, fall, fide, fiduciary, figure, FINRA, Fire, fluctuate, foreseeable, fruition, furnish, GABAAsubtype, governance, governing, government, great, growing, grown, GW, hard, healthcare, heightening, hurt, illustrated, impede, implied, impose, imposed, improper, inability, inaccurate, inefficiency, influence, infrastructure, instrument, intangible, intensify, interfering, invoicing, issuer, knowledge, line, litigation, local, located, lose, loyalty, Manhattan, Matthew, mind, misconduct, modify, momentum, monetary, Nabiximol, neuropathy, newly, nominating, oromucosal, OTC, oversight, oxygen, pattern, PD, penny, Pharma, pharmacodynamic, pilot, Pink, PK, plc, precipitously, Preclincial, prevailing, professional, profitability, prohibit, prosecution, proxy, purity, quotation, rail, rare, recommend, recommended, recommending, recruit, recruiting, reissued, remediate, repurposing, resale, Respire, reverse, risky, screening, seasoned, sentiment, settle, Shane, shortest, speculative, spend, spending, split, sporadically, spouse, spray, spread, steady, strain, successor, suitable, surviving, tandem, tangible, temporary, terminology, THC, thinly, tier, timeframe, titled, tradename, transitional, transparent, trust, trustee, typically, unavailable, undue, uneconomical, unemployment, unenforced, unexpected, unknown, unpredictable, unsafe, upfront, venture, view, viewed, vii, violation, virtually, vitro, voluntarily, webcast, Wisconsin

Removed: aberrant, abnormal, adherence, adulthood, Advancement, affecting, aged, aggression, agonistic, Alberta, allele, amelioration, anesthetic, announce, antagonist, antagonistic, aripiprazole, ASD, attended, autism, autistic, behavioral, biomarker, blind, branded, categorized, CDC, clarified, climate, Clustered, collapsing, comprising, configuration, connectivity, consumption, core, counsel, CRISPR, CSA, curative, desensitization, Diego, disordered, dispute, disputed, disrupted, dominant, double, dramatic, dysfunction, editing, Edmonton, educational, elusive, emotional, environmental, etiologic, etiology, evidenced, expanded, expansion, explore, extreme, facilitation, Fragile, FXS, gene, generation, genome, glutamatergic, granting, guard, healthy, identifiable, inclusion, infection, instability, interpersonal, Interspaced, introduced, invoked, irritability, jaw, language, largest, light, LTF, MAD, malfunction, Mandibular, mask, mechanical, medicinal, modulate, molecular, mood, mutation, naloxone, naturally, negotiate, neurodevelopmental, opening, output, Palindromic, persist, person, phenotype, physical, physiological, play, political, population, positively, prescription, prevalence, prevention, pullback, purported, ranging, reallocate, rebuilding, remained, representation, retained, Retaining, risen, risperidone, San, sense, sequence, sequencing, showed, signal, slightly, smell, spectrum, splint, Stargazin, stimulating, stimuli, studied, studying, subtle, surgically, synapse, syndrome, TEC, teenage, tentatively, thought, Today, trafficking, transmembrane, transmitter, TRD, UCSD, understand, uvulopalatopharyngoplasty, valuable, verbal, voice

From filing 10-Q 2020 Q3